<p>Three Bridge Wealth Advisors LLC 在第二季度購買了 IDEXX Laboratories, Inc. (NASDAQ:IDXX - 免費報告) 的新股份，根據該公司在最近向證券交易委員會的備案中披露。這家機構投資者購買了 454 股公司股票，價值約為 243,000 美元。</p>
<p>獲取 <strong>IDEXX Laboratories</strong> 警報：</p>
<ul>
<li>看漲還是看跌？評估動物醫療股票</li>
</ul>
<p>其他幾家機構投資者和對沖基金最近也對該股票的持倉進行了調整。Red Spruce Capital LLC 在第二季度將其在 IDEXX Laboratories 的持股增加了 1.1%。Red Spruce Capital LLC 現在擁有 1,701 股公司股票，價值 912,000 美元，在此期間又購買了 19 股。Rise Advisors LLC 在第二季度將其在 IDEXX Laboratories 的持倉提高了 3.9%。Rise Advisors LLC 現在擁有 562 股公司股票，價值 301,000 美元，在上個季度又購買了 21 股。Sage Mountain Advisors LLC 在第一季度將其在 IDEXX Laboratories 的持倉提高了 3.8%。Sage Mountain Advisors LLC 現在擁有 635 股公司股票，價值 267,000 美元，在上個季度又購買了 23 股。Great Lakes Advisors LLC 在第一季度將其在 IDEXX Laboratories 的持倉提高了 0.9%。Great Lakes Advisors LLC 現在擁有 2,567 股公司股票，價值 1,078,000 美元，在上個季度又購買了 23 股。最後，PDS Planning Inc 在第一季度將其在 IDEXX Laboratories 的持倉提高了 3.9%。PDS Planning Inc 現在擁有 641 股公司股票，價值 269,000 美元，在上個季度又購買了 24 股。機構投資者和對沖基金持有公司 87.84% 的股票。</p>
<h2>IDEXX Laboratories 股票表現</h2>
<p>NASDAQ IDXX 週五開盤價為 631.19 美元。該公司的 50 日移動平均線為 634.52 美元，200 日移動平均線為 535.57 美元。公司的債務與股本比率為 0.31，速動比率為 0.79，流動比率為 1.11。該股票的市值為 505 億美元，市盈率為 52.56，市盈增長比率為 4.09，貝塔值為 1.58。IDEXX Laboratories, Inc. 的 52 周低點為 356.14 美元，52 周高點為 688.12 美元。</p>
<p>IDEXX Laboratories (NASDAQ:IDXX - 獲取免費報告) 最近於 8 月 4 日星期一發布了季度財報。該公司報告季度每股收益為 3.63 美元，超出分析師一致預期的 3.28 美元，超出幅度為 0.35 美元。IDEXX Laboratories 的淨利潤率為 24.41%，股本回報率為 64.42%。該季度的營業收入為 11.1 億美元，而分析師預期為 10.6 億美元。去年同期，該公司每股收益為 2.44 美元。與去年同期相比，IDEXX Laboratories 本季度的收入增長了 10.6%。IDEXX Laboratories 已設定 2025 財年的每股收益指導為 12.400-12.760 美元。平均而言，賣方分析師預計 IDEXX Laboratories, Inc. 本年度將發佈 11.93 美元的每股收益。</p>
<h2>IDEXX Laboratories 的內部買賣</h2>
<p>在相關消息中，執行副總裁 Nimrata Hunt 於 8 月 6 日星期三出售了 7,143 股公司的股票。股票以 630.43 美元的平均價格出售，總交易額為 4,503,161.49 美元。交易後，該執行副總裁直接持有 18,007 股公司股票，價值約為 11,352,153.01 美元。這筆交易代表其持股減少了 28.40%。該交易已在向證券交易委員會的法律備案中披露，相關信息可通過 SEC 網站獲取。此外，首席執行官 Jonathan Jay Mazelsky 於 8 月 6 日星期三出售了 29,260 股公司的股票。股票以 631.98 美元的平均價格出售，總交易額為 18,491,734.80 美元。交易後，首席執行官直接持有 83,311 股公司股票，價值約為 52,650,885.78 美元。這代表其持股減少了 25.99%。該銷售的披露信息可以在這裏找到。內部人士在上個季度出售了 54,057 股公司股票，價值 34,293,468 美元。公司內部人士持有公司 0.98% 的股票。</p>
<h2>分析師評級上調和下調</h2>
<p>幾家券商最近對 IDXX 發表了評論。華爾街禪在 9 月 28 日星期日的報告中將 IDEXX Laboratories 的股票評級從 “強力買入” 下調至 “買入”。BTIG Research 在 8 月 5 日星期二的報告中將 IDEXX Laboratories 的目標價格從 545.00 美元上調至 785.00 美元，並給予該股票 “買入” 評級。Weiss Ratings 在 9 月 27 日星期六的報告中重申了對 IDEXX Laboratories 的 “買入（b-）” 評級。摩根大通在 8 月 4 日星期一的報告中將 IDEXX Laboratories 的目標價格從 550.00 美元上調至 675.00 美元，並給予該股票 “增持” 評級。最後，Jefferies Financial Group 在 7 月 1 日星期二開始覆蓋 IDEXX Laboratories 的股票。他們設定了 “買入” 評級和 625.00 美元的目標價格。一位研究分析師對該股票給予了強力買入評級，七位給予了買入評級，四位對該公司給予了持有評級。根據 MarketBeat.com，該公司目前的共識評級為 “適度買入”，共識目標價格為 656.50 美元。</p>
<p><strong>閲讀我們最新的 IDXX 股票分析</strong></p>
<h2>IDEXX Laboratories 公司簡介</h2>
<p>（免費報告）</p>
<p>IDEXX Laboratories, Inc. 主要開發、製造和分銷產品，服務於非洲、亞太地區、加拿大、歐洲、拉丁美洲及國際市場的伴侶動物獸醫、牲畜和家禽、乳製品及水質檢測市場。該公司通過三個部門運營：伴侶動物組；水質產品；以及牲畜、家禽和乳製品。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票，勝過 IDEXX 實驗室</li>
<li>比較和交易高市盈率股票</li>
<li>為什麼沒人談論的貴金屬可能是你最好的投資選擇</li>
<li>為什麼投資 5G？如何投資 5G 股票</li>
<li>便宜的 Chipotle？為什麼 CMG 股票可能準備反彈</li>
<li>在 52 周高點盈利交易股票</li>
<li>3 只工業股票準備從美聯儲降息和支出中受益</li>
</ul>
<p><strong>想看看其他對 IDXX 感興趣的對沖基金持有哪些股票嗎？</strong> 訪問 HoldingsChannel.com，獲取 IDEXX 實驗室公司（NASDAQ:IDXX - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SURYWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SURYWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 IDEXX 實驗室嗎？</h2>
<p>在你考慮 IDEXX 實驗室之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前...而 IDEXX 實驗室並不在名單上。</p>
<p>雖然 IDEXX 實驗室目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

IDEXX實驗室

<p>Three Bridge Wealth Advisors LLC 在第二季度收購了 IDEXX Laboratories, Inc. (NASDAQ:IDXX) 的新股份，購買了 454 股，價值約為 243,000 美元。其他機構投資者也調整了他們在該股票上的持倉。IDEXX Laboratories 報告了強勁的季度收益，收入為 11.1 億美元，每股收益為 3.63 美元，超出分析師的預期。該股票目前的交易價格為 631.19 美元，市值為 505 億美元。近期注意到內部人士的拋售，執行官們出售了大量股份</p>

<p>Three Bridge Wealth Advisors LLC purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The institutional investor purchased 454 shares of the company's stock, valued at approximately $243,000.</p>
<div class="lb-trans"><p>Three Bridge Wealth Advisors LLC 在第二季度購買了 IDEXX Laboratories, Inc. (NASDAQ:IDXX - 免費報告) 的新股份，根據該公司在最近向證券交易委員會的備案中披露。這家機構投資者購買了 454 股公司股票，價值約為 243,000 美元。</p>
</div><p>Get <strong>IDEXX Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>IDEXX Laboratories</strong> 警報：</p>
</div><ul>
<li>Bullish or Bearish? Vetting Animal Health Care Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>看漲還是看跌？評估動物醫療股票</li>
</ul>
</div><p>Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Red Spruce Capital LLC boosted its holdings in shares of IDEXX Laboratories by 1.1% in the second quarter. Red Spruce Capital LLC now owns 1,701 shares of the company's stock valued at $912,000 after buying an additional 19 shares during the period. Rise Advisors LLC raised its position in IDEXX Laboratories by 3.9% in the 2nd quarter. Rise Advisors LLC now owns 562 shares of the company's stock valued at $301,000 after buying an additional 21 shares during the last quarter. Sage Mountain Advisors LLC raised its position in IDEXX Laboratories by 3.8% in the 1st quarter. Sage Mountain Advisors LLC now owns 635 shares of the company's stock valued at $267,000 after buying an additional 23 shares during the last quarter. Great Lakes Advisors LLC raised its position in IDEXX Laboratories by 0.9% in the 1st quarter. Great Lakes Advisors LLC now owns 2,567 shares of the company's stock valued at $1,078,000 after buying an additional 23 shares during the last quarter. Finally, PDS Planning Inc raised its position in IDEXX Laboratories by 3.9% in the 1st quarter. PDS Planning Inc now owns 641 shares of the company's stock valued at $269,000 after buying an additional 24 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家機構投資者和對沖基金最近也對該股票的持倉進行了調整。Red Spruce Capital LLC 在第二季度將其在 IDEXX Laboratories 的持股增加了 1.1%。Red Spruce Capital LLC 現在擁有 1,701 股公司股票，價值 912,000 美元，在此期間又購買了 19 股。Rise Advisors LLC 在第二季度將其在 IDEXX Laboratories 的持倉提高了 3.9%。Rise Advisors LLC 現在擁有 562 股公司股票，價值 301,000 美元，在上個季度又購買了 21 股。Sage Mountain Advisors LLC 在第一季度將其在 IDEXX Laboratories 的持倉提高了 3.8%。Sage Mountain Advisors LLC 現在擁有 635 股公司股票，價值 267,000 美元，在上個季度又購買了 23 股。Great Lakes Advisors LLC 在第一季度將其在 IDEXX Laboratories 的持倉提高了 0.9%。Great Lakes Advisors LLC 現在擁有 2,567 股公司股票，價值 1,078,000 美元，在上個季度又購買了 23 股。最後，PDS Planning Inc 在第一季度將其在 IDEXX Laboratories 的持倉提高了 3.9%。PDS Planning Inc 現在擁有 641 股公司股票，價值 269,000 美元，在上個季度又購買了 24 股。機構投資者和對沖基金持有公司 87.84% 的股票。</p>
</div><h2>IDEXX Laboratories Stock Performance</h2>
<div class="lb-trans"><h2>IDEXX Laboratories 股票表現</h2>
</div><p>NASDAQ IDXX opened at $631.19 on Friday. The firm has a 50-day moving average of $634.52 and a 200-day moving average of $535.57. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. The stock has a market cap of $50.50 billion, a PE ratio of 52.56, a P/E/G ratio of 4.09 and a beta of 1.58. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $688.12.</p>
<div class="lb-trans"><p>NASDAQ IDXX 週五開盤價為 631.19 美元。該公司的 50 日移動平均線為 634.52 美元，200 日移動平均線為 535.57 美元。公司的債務與股本比率為 0.31，速動比率為 0.79，流動比率為 1.11。該股票的市值為 505 億美元，市盈率為 52.56，市盈增長比率為 4.09，貝塔值為 1.58。IDEXX Laboratories, Inc. 的 52 周低點為 356.14 美元，52 周高點為 688.12 美元。</p>
</div><p>IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, topping analysts' consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same period last year, the firm earned $2.44 earnings per share. IDEXX Laboratories's revenue for the quarter was up 10.6% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.</p>
<div class="lb-trans"><p>IDEXX Laboratories (NASDAQ:IDXX - 獲取免費報告) 最近於 8 月 4 日星期一發布了季度財報。該公司報告季度每股收益為 3.63 美元，超出分析師一致預期的 3.28 美元，超出幅度為 0.35 美元。IDEXX Laboratories 的淨利潤率為 24.41%，股本回報率為 64.42%。該季度的營業收入為 11.1 億美元，而分析師預期為 10.6 億美元。去年同期，該公司每股收益為 2.44 美元。與去年同期相比，IDEXX Laboratories 本季度的收入增長了 10.6%。IDEXX Laboratories 已設定 2025 財年的每股收益指導為 12.400-12.760 美元。平均而言，賣方分析師預計 IDEXX Laboratories, Inc. 本年度將發佈 11.93 美元的每股收益。</p>
</div><h2>Insider Buying and Selling at IDEXX Laboratories</h2>
<div class="lb-trans"><h2>IDEXX Laboratories 的內部買賣</h2>
</div><p>In related news, EVP Nimrata Hunt sold 7,143 shares of the firm's stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $630.43, for a total transaction of $4,503,161.49. Following the transaction, the executive vice president directly owned 18,007 shares of the company's stock, valued at approximately $11,352,153.01. This trade represents a 28.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through the SEC website. Also, CEO Jonathan Jay Mazelsky sold 29,260 shares of the firm's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $631.98, for a total transaction of $18,491,734.80. Following the transaction, the chief executive officer directly owned 83,311 shares in the company, valued at approximately $52,650,885.78. This represents a 25.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 54,057 shares of company stock valued at $34,293,468 in the last quarter. Company insiders own 0.98% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，執行副總裁 Nimrata Hunt 於 8 月 6 日星期三出售了 7,143 股公司的股票。股票以 630.43 美元的平均價格出售，總交易額為 4,503,161.49 美元。交易後，該執行副總裁直接持有 18,007 股公司股票，價值約為 11,352,153.01 美元。這筆交易代表其持股減少了 28.40%。該交易已在向證券交易委員會的法律備案中披露，相關信息可通過 SEC 網站獲取。此外，首席執行官 Jonathan Jay Mazelsky 於 8 月 6 日星期三出售了 29,260 股公司的股票。股票以 631.98 美元的平均價格出售，總交易額為 18,491,734.80 美元。交易後，首席執行官直接持有 83,311 股公司股票，價值約為 52,650,885.78 美元。這代表其持股減少了 25.99%。該銷售的披露信息可以在這裏找到。內部人士在上個季度出售了 54,057 股公司股票，價值 34,293,468 美元。公司內部人士持有公司 0.98% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調和下調</h2>
</div><p>Several brokerages recently commented on IDXX. Wall Street Zen cut shares of IDEXX Laboratories from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Sunday, September 28th. BTIG Research increased their target price on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, August 5th. Weiss Ratings restated a &#34;buy (b-)&#34; rating on shares of IDEXX Laboratories in a report on Saturday, September 27th. JPMorgan Chase &amp; Co. increased their target price on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the stock an &#34;overweight&#34; rating in a report on Monday, August 4th. Finally, Jefferies Financial Group began coverage on shares of IDEXX Laboratories in a report on Tuesday, July 1st. They set a &#34;buy&#34; rating and a $625.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $656.50.</p>
<div class="lb-trans"><p>幾家券商最近對 IDXX 發表了評論。華爾街禪在 9 月 28 日星期日的報告中將 IDEXX Laboratories 的股票評級從 “強力買入” 下調至 “買入”。BTIG Research 在 8 月 5 日星期二的報告中將 IDEXX Laboratories 的目標價格從 545.00 美元上調至 785.00 美元，並給予該股票 “買入” 評級。Weiss Ratings 在 9 月 27 日星期六的報告中重申了對 IDEXX Laboratories 的 “買入（b-）” 評級。摩根大通在 8 月 4 日星期一的報告中將 IDEXX Laboratories 的目標價格從 550.00 美元上調至 675.00 美元，並給予該股票 “增持” 評級。最後，Jefferies Financial Group 在 7 月 1 日星期二開始覆蓋 IDEXX Laboratories 的股票。他們設定了 “買入” 評級和 625.00 美元的目標價格。一位研究分析師對該股票給予了強力買入評級，七位給予了買入評級，四位對該公司給予了持有評級。根據 MarketBeat.com，該公司目前的共識評級為 “適度買入”，共識目標價格為 656.50 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on IDXX</strong></p>
<div class="lb-trans"><p><strong>閲讀我們最新的 IDXX 股票分析</strong></p>
</div><h2>IDEXX Laboratories Profile</h2>
<div class="lb-trans"><h2>IDEXX Laboratories 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.</p>
<div class="lb-trans"><p>IDEXX Laboratories, Inc. 主要開發、製造和分銷產品，服務於非洲、亞太地區、加拿大、歐洲、拉丁美洲及國際市場的伴侶動物獸醫、牲畜和家禽、乳製品及水質檢測市場。該公司通過三個部門運營：伴侶動物組；水質產品；以及牲畜、家禽和乳製品。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than IDEXX Laboratories</li>
<li>Comparing and Trading High PE Ratio Stocks</li>
<li>Why the Precious Metal Nobody Talks About Could Be Your Best Bet</li>
<li>Why Invest in 5G? How to Invest in 5G Stocks</li>
<li>Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback</li>
<li>Profitably Trade Stocks at 52-Week Highs</li>
<li>3 Industrial Stocks Ready to Benefit From Fed Cuts and Spending</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 IDEXX 實驗室</li>
<li>比較和交易高市盈率股票</li>
<li>為什麼沒人談論的貴金屬可能是你最好的投資選擇</li>
<li>為什麼投資 5G？如何投資 5G 股票</li>
<li>便宜的 Chipotle？為什麼 CMG 股票可能準備反彈</li>
<li>在 52 周高點盈利交易股票</li>
<li>3 只工業股票準備從美聯儲降息和支出中受益</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding IDXX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 IDXX 感興趣的對沖基金持有哪些股票嗎？</strong> 訪問 HoldingsChannel.com，獲取 IDEXX 實驗室公司（NASDAQ:IDXX - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SURYWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=IDXX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in IDEXX Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 IDEXX 實驗室嗎？</h2>
</div><p>Before you consider IDEXX Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 IDEXX 實驗室之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前...而 IDEXX 實驗室並不在名單上。</p>
</div><p>While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 IDEXX 實驗室目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Three Bridge Wealth Advisors LLC 建立了在 IDEXX 實驗室公司的持倉 $IDXX